1 Magnificent Dividend Stock to Buy and Hold [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Ideally, income-seeking investors want to avoid these situations. They prefer dividend-paying companies that can afford to raise their payouts regularly and aren't at risk of reducing or suspending their dividend programs. Let's look at one stock that can give income-seekers precisely what they want: Swiss pharma giant Novartis (NYSE: NVS) The underlying business is strong Novartis is one of the largest drugmakers in the world, with a deep lineup of medicines, many of which make over $1 billion per year. Of the 13 blockbusters it had in its portfolio last year, 10 grew their sales year over year. Novartis' top-selling product remains Entresto, a medicine for heart failure. Entresto's revenue increased by 30% year over year to about $6 billion. Meanwhile, Novartis' Pluvicto, a prostate cancer medicine first approved in the U.S. in 2022, is flying high. It ended the year with sales of $980 million, an increase of 262% year over year. Though several of Novartis' products are se
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases [Yahoo! Finance]Yahoo! Finance
- 20 Countries with the Highest Rates of Stomach Cancer in the World [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NYSE: NVS) had its price target raised by analysts at BMO Capital Markets from $114.00 to $116.00. They now have a "market perform" rating on the stock.MarketBeat
- Roche Sales Decline in Last Quarter of Pandemic Impact [BNN Bloomberg (Canada)]BNN Bloomberg
- Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- NVS's page on the SEC website